Skip to main content
. 2020 Apr 22;10:6825. doi: 10.1038/s41598-020-63818-7

Figure 4.

Figure 4

BBT-059 administration promoted sternal bone marrow hematopoietic cell recovery after lethal dose of TBI. Increases in bone marrow cellularity and megakaryocytes were observed after 30 days in the Drug treatment group. There was no difference between FB and BBT-059 treated groups at 6 and 12 months post-TBI. Data represented are mean ± standard error of the mean (SEM).